Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 8/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16322018 | 1.00 | CYP3A4 (0.65) | CYP3A4CYP2B6SMN1; SMN2HTTMMP9 | |
| SCHEMBL16321728 | 1.00 | CYP3A4 (0.65) | CYP3A4CYP2B6SMN1; SMN2HTTMMP9 | |
| SCHEMBL16321729 | 1.00 | CYP3A4 (0.65) | CYP3A4CYP2B6SMN1; SMN2HTTMMP9 | |
| SCHEMBL16364785 | 0.85 | CYP3A4 (0.63) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| SCHEMBL21667273 | 0.84 | SMN1; SMN2 (0.44) | CYP3A4CYP2B6SMN1; SMN2HTTTP53 | |
| SCHEMBL16356126 | 0.83 | CYP3A4 (0.76) | CYP3A4CYP2B6SMN1; SMN2HTTTP53 | |
| SCHEMBL16322276 | 0.83 | CYP3A4 (0.62) | CYP3A4CYP2B6SMN1; SMN2HTTMMP9 | |
| SCHEMBL16322278 | 0.83 | CYP3A4 (0.62) | CYP3A4CYP2B6SMN1; SMN2HTTMMP9 | |
| SCHEMBL16322227 | 0.82 | CYP3A4 (0.74) | CYP3A4CYP2B6SMN1; SMN2HTTTP53 | |
| SCHEMBL20547251 | 0.82 | CYP3A4 (0.74) | CYP3A4CYP2B6SMN1; SMN2HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.